Menu

FDA Seeks to Block Two Unregulated Stem Cell Clinics

Two patients became legally blind after receiving treatments at the facilities.

May 11, 2018
Jim Daley

FLICKR, FDA

On Wednesday (May 9), the Food and Drug Administration announced that it is requesting injunctions in federal courts against two stem cell clinics, one based in California and another in Florida, that would force them to stop operating. Two former patients are suing the cell shops, saying they went blind after receiving treatments at them, according to The Washington Post.

See “Women Lose Vision After Stem Cell Treatment

“Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk,” says FDA Commissioner Scott Gottlieb in a press release. “In some instances, patients have suffered serious and permanent harm after receiving these unapproved products. In the two cases filed today, the clinics and their leadership have continued to disregard the law and more importantly, patient safety.”

The FDA warned US Stem Cell in Florida and the California Stem Cell Treatment Center that it had “serious concerns” about their practices in August 2017, according to STAT News. In the press release, the FDA says the clinics “did not address the violations” described in the warning letter.

See “Texas Stem Cell Law Opens Door for Controversial Treatments

In a statement, US Stem Cell says it intends “to vigorously defend” the lawsuit. “My entire career has been dedicated to studying and developing treatments utilizing the body’s own natural ability to heal,” says Kristin Comella, the clinic’s chief science officer, in a statement quoted in The Post. “I remain steadfast that no government agency should deprive individuals of their right to harness the cells that exist in their body.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!